Literature DB >> 3536746

Strain variation in composition and molecular size of the capsular polysaccharide of Cryptococcus neoformans serotype A.

J M Small, T G Mitchell, R W Wheat.   

Abstract

The capsule of Cryptococcus neoformans is an important virulence factor. In this investigation capsular polysaccharides (CPSs) were isolated by ethanol precipitation from culture filtrates of C. neoformans serotype A strains 6, 15, 98, 110, and 145. Capsule sizes on India ink examination ranged from barely perceptible (strain 15) to greater than the diameter of the yeast cell (strain 6); the others were intermediate in size. On ion-exchange chromatography on DEAE-cellulose each CPS eluted at 0.2 M NaCl; CPS of strain 15 had two major peaks, designated III and IV. On gel-permeation chromatography CPSs of strains 6, 98, 110, and 145 eluted at the void volume of Sepharose CL-2B in the presence or 0.1 M EDTA, while the CPS of strain 15 eluted in two peaks. Sephacryl S-1000 resolved CPSs of all five strains in the following order, from largest to smallest molecular size: 145 greater than 110 greater than 98 greater than 6 much greater than 15. All five CPSs contained mannose, xylose, and glucuronic acid, while the carboxyl-reduced CPS of strain 110 also contained a large percentage of an inositol-like compound. The CPS of strain 110 contained approximately 30% uronic acid by weight, while the others had 15 to 20%. The composition of peak IV from the CPS of strain 15 resembled those of the other strains; peak III of strain 15 contained a substantial amount of galactose. Each CPS contained less than 0.2% protein by weight. The significant differences in molecular size and sugar composition among CPSs of these strains of C. neoformans serotype A may partially explain strain differences in virulence and biological properties of the organism.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3536746      PMCID: PMC260231          DOI: 10.1128/iai.54.3.735-741.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection.

Authors:  R D Diamond; J E May; M A Kane; M M Frank; J E Bennett
Journal:  J Immunol       Date:  1974-06       Impact factor: 5.422

2.  New method for quantitative determination of uronic acids.

Authors:  N Blumenkrantz; G Asboe-Hansen
Journal:  Anal Biochem       Date:  1973-08       Impact factor: 3.365

3.  Stoichiometric depolymerization of polyuronides and glycosaminoglycuronans to monosaccharides following reduction of their carbodiimide-activated carboxyl groups.

Authors:  R L Taylor; H E Conrad
Journal:  Biochemistry       Date:  1972-04-11       Impact factor: 3.162

4.  Pigment production by Cryptococcus neoformans from para- and ortho-Diphenols: effect of the nitrogen source.

Authors:  S Chaskes; R L Tyndall
Journal:  J Clin Microbiol       Date:  1975-06       Impact factor: 5.948

5.  Fractionation and characterization of galactoxylomannan from Cryptococcus neoformans.

Authors:  S H Turner; R Cherniak; E Reiss
Journal:  Carbohydr Res       Date:  1984-02-15       Impact factor: 2.104

6.  Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype A.

Authors:  R Cherniak; E Reiss; M E Slodki; R D Plattner; S O Blumer
Journal:  Mol Immunol       Date:  1980-08       Impact factor: 4.407

7.  Chemical characterization of capsular polysaccharide from Cryptococcus neoformans serotype A-D.

Authors:  R Ikeda; A Nishikawa; T Shinoda; Y Fukazawa
Journal:  Microbiol Immunol       Date:  1985       Impact factor: 1.955

8.  Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide.

Authors:  T R Kozel; J Cazin
Journal:  Infect Immun       Date:  1971-02       Impact factor: 3.441

9.  Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique.

Authors:  J W Murphy; G C Cozad
Journal:  Infect Immun       Date:  1972-06       Impact factor: 3.441

10.  Decreased virulence in stable, acapsular mutants of cryptococcus neoformans.

Authors:  R A Fromtling; H J Shadomy; E S Jacobson
Journal:  Mycopathologia       Date:  1982-07-23       Impact factor: 2.574

View more
  13 in total

1.  Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation.

Authors:  S M Levitz; T S Harrison; A Tabuni; X Liu
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

2.  Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody.

Authors:  M F Miller; T G Mitchell; W J Storkus; J R Dawson
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

Review 3.  Current concepts in cryptococcosis.

Authors:  T F Patterson; V T Andriole
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-05       Impact factor: 3.267

4.  Binding of purified and radioiodinated capsular polysaccharides from Cryptococcus neoformans serotype A strains to capsule-free mutants.

Authors:  J M Small; T G Mitchell
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

5.  Facilitated isolation, purification, and analysis of glucuronoxylomannan of Cryptococcus neoformans.

Authors:  R Cherniak; L C Morris; B C Anderson; S A Meyer
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

6.  Killing of Cryptococcus neoformans strains by human neutrophils and monocytes.

Authors:  M F Miller; T G Mitchell
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

7.  Molecular typing of Cryptococcus neoformans serotype D clinical isolates.

Authors:  F Dromer; A Varma; O Ronin; S Mathoulin; B Dupont
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

8.  High detection rates of cryptococcal antigen in pulmonary cryptococcosis by Eiken latex agglutination test with pronase pretreatment.

Authors:  S Kohno; A Yasuoka; H Koga; M Kaku; S Maesaki; K Tanaka; K Mitsutake; H Matsuda; K Hara
Journal:  Mycopathologia       Date:  1993-08       Impact factor: 2.574

9.  Effect of polysaccharide capsule and methods of preparation on human lymphocyte proliferation in response to Cryptococcus neoformans.

Authors:  C H Mody; R M Syme
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

10.  Strain variation in antiphagocytic activity of capsular polysaccharides from Cryptococcus neoformans serotype A.

Authors:  J M Small; T G Mitchell
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.